Daniela Hoehn

2.1k total citations
50 papers, 674 citations indexed

About

Daniela Hoehn is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Daniela Hoehn has authored 50 papers receiving a total of 674 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 24 papers in Oncology and 19 papers in Genetics. Recurrent topics in Daniela Hoehn's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Daniela Hoehn is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Daniela Hoehn collaborates with scholars based in United States, Netherlands and France. Daniela Hoehn's co-authors include L. Jeffrey Medeiros, Govind Bhagat, Rashmi Kanagal‐Shamanna, Bachir Alobeid, Carlos E. Bueso‐Ramos, Pei Lin, Kun Wang, Matthew D. Keller, Kamraan Z. Gill and Vundavalli V. Murty and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Daniela Hoehn

48 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniela Hoehn United States	15	276	257	219	199	188	50	674
Claudia Corrado Argentina	14	207 0.8×	206 0.8×	336 1.5×	265 1.3×	115 0.6×	28	661
Debora Capelli Italy	14	175 0.6×	390 1.5×	73 0.3×	199 1.0×	133 0.7×	27	542
J.J. Sotto France	11	179 0.6×	148 0.6×	238 1.1×	178 0.9×	186 1.0×	17	565
JD Tigaud France	7	162 0.6×	354 1.4×	157 0.7×	219 1.1×	121 0.6×	13	539
Brigitte Kolb France	9	373 1.4×	426 1.7×	243 1.1×	238 1.2×	208 1.1×	25	728
Isabelle Genvresse Germany	12	107 0.4×	169 0.7×	104 0.5×	157 0.8×	99 0.5×	27	472
Kang Howson‐Jan Canada	12	137 0.5×	404 1.6×	154 0.7×	203 1.0×	189 1.0×	33	666
Susana Vives Spain	10	272 1.0×	533 2.1×	66 0.3×	209 1.1×	152 0.8×	37	791
Phillip Barnette United States	11	189 0.7×	178 0.7×	123 0.6×	255 1.3×	48 0.3×	26	672
Deborah Fuchs United States	8	368 1.3×	606 2.4×	102 0.5×	101 0.5×	310 1.6×	20	882

Countries citing papers authored by Daniela Hoehn

Since Specialization

Citations

This map shows the geographic impact of Daniela Hoehn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Hoehn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Hoehn more than expected).

Fields of papers citing papers by Daniela Hoehn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Hoehn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Hoehn. The network helps show where Daniela Hoehn may publish in the future.

Co-authorship network of co-authors of Daniela Hoehn

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Hoehn. A scholar is included among the top collaborators of Daniela Hoehn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Hoehn. Daniela Hoehn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7. Clinical Lymphoma Myeloma & Leukemia. 24. S496–S497. 1 indexed citations

2.

Morschhauser, Franck, David Belada, Johannes Duell, et al.. (2024). Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma. Blood. 144(Supplement 1). 867–867. 4 indexed citations

3.

Vose, Julie M., Umberto Vitolo, Pieternella J. Lugtenburg, et al.. (2024). EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL.. Journal of Clinical Oncology. 42(16_suppl). 7015–7015. 9 indexed citations

4.

Falchi, Lorenzo, Anna Sureda, Sirpa Leppä, et al.. (2024). Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial. Blood. 144(Supplement 1). 342–342. 5 indexed citations

5.

Falchi, Lorenzo, Joost S.P. Vermaat, Gerardo Musuraca, et al.. (2024). Epcoritamab with rituximab + lenalidomide (R²) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7.. Journal of Clinical Oncology. 42(16_suppl). 7014–7014. 3 indexed citations

6.

Kater, Arnon P., Jose Sandoval‐Sus, Mar Bellido, et al.. (2022). Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1). Blood. 140(Supplement 1). 850–851. 25 indexed citations

7.

Voorhees, Peter M., Cesar Rodriguez, Brandi Reeves, et al.. (2021). Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Advances. 5(4). 1092–1096. 18 indexed citations

8.

Amengual, Jennifer E., Paul Johannet, Maximilian Lombardo, et al.. (2015). Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clinical Cancer Research. 21(20). 4663–4675. 71 indexed citations

9.

Gill, Kamraan Z., et al.. (2014). C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?. Leukemia Research. 38(9). 1061–1066. 14 indexed citations

10.

Gill, Kamraan Z., Fábio M. Iwamoto, Daniela Hoehn, et al.. (2014). MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. PLoS ONE. 9(12). e114398–e114398. 30 indexed citations

11.

Lee, John C., Daniela Hoehn, Jordan M. Schecter, et al.. (2013). Lymphoid follicle colonization by Bcl-2bright+CD10+ B-cells (“follicular lymphoma in situ”) at nodal and extranodal sites can be a manifestation of follicular homing of lymphoma. Human Pathology. 44(7). 1328–1340. 7 indexed citations

12.

Jabbour, Elias, Deborah A. Thomas, Guillermo Garcia‐Manero, et al.. (2013). Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood. 122(21). 2664–2664. 15 indexed citations

13.

Hoehn, Daniela, Sergej Konoplev, & C. Cameron Yin. (2012). Unusual Presentation of a Dysembryoplastic Neuroepithelial Tumor Mimicking a Pontomesencephalic Cavernous Hemangioma. Journal of Medical Cases. 3(6). 375–378. 2 indexed citations

14.

Hoehn, Daniela, L. Jeffrey Medeiros, Hagop M. Kantarjian, et al.. (2012). Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia. Human Pathology. 43(12). 2354–2359. 5 indexed citations

15.

Hoeller, Sylvia, Rashmi Kanagal‐Shamanna, Zijun Y. Xu‐Monette, et al.. (2012). Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Human Pathology. 44(1). 110–121. 23 indexed citations

16.

Hoehn, Daniela, Roberto N. Miranda, Rashmi Kanagal‐Shamanna, Pei Lin, & L. Jeffrey Medeiros. (2012). Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Human Pathology. 43(11). 1828–1838. 13 indexed citations

17.

Friedman, Mark T., et al.. (2012). Informed Consent for Blood Transfusion. American Journal of Clinical Pathology. 138(4). 559–565. 36 indexed citations

18.

Hoehn, Daniela, et al.. (2011). Parinaud Oculoglandular Syndrome as a Prominent Presenting Feature of Kikuchi-Fujimoto Disease � A Case Report and Review of the Literature. North American Journal of Medicine and Science. 4(2). 96–96. 2 indexed citations

19.

Kanagal‐Shamanna, Rashmi, Carlos E. Bueso‐Ramos, Bedia A. Barkoh, et al.. (2011). Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild‐type TP53. Cancer. 118(11). 2879–2888. 49 indexed citations

20.

Hoehn, Daniela, et al.. (2011). Parinaud Oculoglandular Syndrome as a Prominent Presenting Feature of Kikuchi-Fujimoto Disease � A Case Report and Review of the Literature. North American Journal of Medicine and Science. 4(2). 96–96. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact